Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02833701 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma
A Phase 1 study, sponsored by University of Nebraska.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02833701 is a Phase 1 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 9 participants.
The verdict
NCT02833701, a Phase 1 study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of ascorbic acid when given together with bevacizumab in treating patients with high grade glioma that has come back (recurrent). Monoclonal antibodies, such as bevacizumab may interfere with the ability of tumor cells to grow and spread. Ascorbic acid contains ingredients that may prevent or slow the growth of high grade glioma. Giving bevacizumab and ascorbic acid together may work better in treating patients with high grade glioma.
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Bevacizumab
- DIETARY_SUPPLEMENT Ascorbic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-03 |
| Est. Completion | 2019-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02833701
The ClinicalTrials.gov registry entry for NCT02833701 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02833701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02833701 about?
NCT02833701 is a clinical study titled "Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma". This phase I trial studies the side effects and best dose of ascorbic acid when given together with bevacizumab in treating patients with high grade glioma that has come back (recurrent). Monoclonal antibodies, such as bevacizumab may interfere with the ability of tumor cells to grow and spread. Asc...
What is the current status of trial NCT02833701?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2016-03. Estimated completion is 2019-03.
What interventions are being tested in trial NCT02833701?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Bevacizumab (BIOLOGICAL), Ascorbic Acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02833701?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.